NCT03049488View on ClinicalTrials.gov

Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

October 3, 2019

Study Completion Date

October 3, 2019

Conditions
Respiratory Syncytial Virus
Interventions
BIOLOGICAL

VRC-RSVRGP084-00-VP

VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.

OTHER

Aluminum Hydroxide Suspension

Aluminum Hydroxide Suspension, alum, is an adjuvant.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03049488 - Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults | Biotech Hunter | Biotech Hunter